Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Efficacy of Ivabradine Versus Metoprolol (IMAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01755663
Recruitment Status : Unknown
Verified October 2014 by Col. Suthee Panichkul, Phramongkutklao College of Medicine and Hospital.
Recruitment status was:  Not yet recruiting
First Posted : December 24, 2012
Last Update Posted : October 29, 2014
Sponsor:
Collaborator:
Phramongkutklao College of Medicine and Hospital
Information provided by (Responsible Party):
Col. Suthee Panichkul, Phramongkutklao College of Medicine and Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Ivabradine may be better than Metoprolol for controlling heart rate before Coronary CTA.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: Ivabradine and Metoprolol Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Diagnostic
Official Title: Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients
Study Start Date : December 2014
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Ivabradine
Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
 Drug: Ivabradine and Metoprolol
Active Comparator: metoprolol
Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
 Drug: Ivabradine and Metoprolol


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Heart rate of patient before CT coronary [ Time Frame: 1 January 2013 to 31 december 2013 ]

Secondary Outcome Measures :
  1. safety and side effect of Metoprolol and Ivabradine [ Time Frame: 1 january 2013 to 31 december 2013 ]

Other Outcome Measures:
  1. Image quality [ Time Frame: 1 january 2013 to 31 december 2013 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective patient on scheduled for 640 slices CT coronary at Phramonkutklao hospital
  • Resting heart rate > 70 BPM
  • age > 18 years and informed consent

Exclusion Criteria:

  • Heart rate > 100 BPM
  • BP <100/60 mmHg
  • recent congestive heart failure in 1 mo.
  • SA node, AV node disease and AF
  • on permanent pacemaker
  • CrCL < 15ml/min. , AST or ALT > 3x UNL
  • on HR reducing drug such as diltiazem, verapamil, digitalis
  • contraindication for ivabradine or metoprolol
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01755663


Contacts
Layout table for location contacts
Contact: Purich Surunchupakorn, M.D. 081-988-7390 winnermd57@gmail.com

Locations
Layout table for location information
Thailand
Phramonkutklao Hospital
Bangkok, Thailand, 10400
Contact: Purich Surunchupakorn, M.D.    081-988-7390    winnermd57@gmail.com   
Principal Investigator: Purich - Surunchupakorn, M.D.         
Sponsors and Collaborators
Col. Suthee Panichkul
Phramongkutklao College of Medicine and Hospital
Investigators
Layout table for investigator information
Principal Investigator: Purich - Surunchupakorn, M.D. Phramongkutklao College of Medicine and Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Col. Suthee Panichkul, Phramongkutklao College of Medicine and Hospital
ClinicalTrials.gov Identifier: NCT01755663    
Other Study ID Numbers: Pharmongkutklao
First Posted: December 24, 2012    Key Record Dates
Last Update Posted: October 29, 2014
Last Verified: October 2014
Keywords provided by Col. Suthee Panichkul, Phramongkutklao College of Medicine and Hospital:
CT coronary
Coronary arterial disease
ivabradine
metoprolol
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Metoprolol
Anti-Arrhythmia Agents
Antihypertensive Agents
 Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action